As part of the Hatch-Waxman Act, given the lack of information on the allegedly infringing product, courts have found that patentees can satisfy the pleading requirements of Twombly/Iqbal without having access to the accused...more
10/31/2023
/ Abbreviated New Drug Application (ANDA) ,
Federal Rules of Civil Procedure ,
Hatch-Waxman ,
Novartis ,
Orange Book ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Pleading Standards ,
Popular ,
Twombly/Iqbal Pleading Standard